It is reported that ovarian cancer cells show differential sensitivity to PARG and PARP inhibitors, and cells with replication vulnerability show persistent replication fork stalling and replication catastrophe, with treatment of the PARG inhibitor and sensitization to CHK1 inhibitor [35]. Here, PARP1 is linked to ovarian carcinoma.